Good 20-Year Patency for Radial Artery Grafts in CABG

Share this content:
Good 20-Year Patency for Radial Artery Grafts in CABG
Good 20-Year Patency for Radial Artery Grafts in CABG

TUESDAY, Aug. 2, 2016 (HealthDay News) -- The 20-year patency rate is good for patients who use the radial artery (RA) as a coronary bypass conduit, according to research published in the Aug. 9 issue of the Journal of the American College of Cardiology.

Mario Gaudino, M.D., from the Catholic University in Rome, and colleagues present 20-year results of RA grafts used for coronary artery bypass grafting in the first 100 patients who received the RA as a coronary bypass conduit.

The researchers found that there were 64 deaths, 35.9 percent of which were from cardiovascular causes. Twenty-year survival was 31 percent. Overall, 91.6 percent of the 36 survivors underwent RA graft control at a mean of 19.0 ± 2.5 years after surgery. RA patency was 84.8 percent. The probability of graft failure was 19.0 ± 0.2 percent for the left internal thoracic artery (ITA), 25.0 ± 0.2 percent for the RA, and 55.0 ± 0.2 percent for the saphenous vein in the overall population at 20 years (P = 0.002 for RA versus saphenous vein; P = 0.11 for RA versus ITA; and P < 0.001 for ITA versus saphenous vein). Target vessel stenosis >90 percent significantly influenced long-term graft patency, but location of distal anastomosis did not.

"The 20-year patency rate of RA grafts is good, and not inferior to the ITA, especially when the conduit is used to graft a vessel with >90 percent stenosis," the authors write.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

SABCS: Artificial Intelligence May Aid Doctors in Breast Cancer Care

SABCS: Artificial Intelligence May Aid Doctors in Breast ...

'Watson Oncology' agreed with doctors 90 percent of the time in many cases, researchers find

SABCS: Scalp-Cooling System Can Reduce Chemo-Related Hair Loss

SABCS: Scalp-Cooling System Can Reduce Chemo-Related Hair Loss

Devices reduce blood flow to hair follicles during chemotherapy treatments

SABCS: Aromatase Inhibitors Tied to Reduced Endothelial Function

SABCS: Aromatase Inhibitors Tied to Reduced Endothelial Function

Women on aromatase inhibitors exhibit less elasticity in their blood vessels

is free, fast, and customized just for you!

Already a member?

Sign In Now »